申请人:Fujisawa Pharmaceutical Co., Ltd.
公开号:US04612376A1
公开(公告)日:1986-09-16
New pyrimidine derivatives of the formula: ##STR1## wherein Z is a group selected from ##STR2## in which R.sup.1 and R.sup.2 are each hydrogen, alkenyl, ar(lower)alkyl or lower alkyl optionally substituted with epoxy, hydroxy, amino and/or lower alkylamino and R.sup.5 is lower alkyl, R.sup.3 is hydrogen, aryl optionally substituted with lower alkyl, lower alkoxy and/or halogen, or pyridyl optionally substituted with lower alkyl, R.sup.4 is hydrogen, lower alkyl or phenyl optionally substituted with lower alkoxy, and Y is .dbd.O, .dbd.S or .dbd.N--R.sup.6, in which R.sup.6 is lower alkyl; cyclo(lower)alkyl; ar(lower)alkyl optionally substituted with lower alkoxy; N-containing unsaturated heterocyclic group optionally substituted with lower alkyl; or aryl optionally substituted with hydroxy, lower alkyl, halogen or lower alkoxy, in which lower alkoxy substituent may be substituted with epoxy, hydroxy, amino and/or lower alkylamino, provided that Y is .dbd.N--R.sup.6 when R.sup.3 and R.sup.4 are each hydrogen, and Y is .dbd.S or .dbd.N--R.sup.6 when R.sup.1 and R.sup.2 are each hydrogen or lower alkyl and R.sup.3 is phenyl, and pharmaceutically acceptable salts thereof, and processes for preparation thereof and pharmaceutical composition comprising the same. These derivatives and salts thereof are useful as cardiotonic, antihypertensive agent, cerebrovascular vasodilator and anti-platelet agent.
新型嘧啶衍生物,其通式为:##STR1## 其中Z为选自##STR2##的基团,其中R1和R2各自为氢、烯基、芳基(低级)烷基或低级烷基,任选地被环氧、羟基、氨基和/或低级烷基氨基取代,R5为低级烷基,R3为氢、任选被低级烷基、低级烷氧基和/或卤素取代的芳基,或任选被低级烷基取代的吡啶基,R4为氢、低级烷基或任选被低级烷氧基取代的苯基,Y为=O、=S或=N--R6,其中R6为低级烷基;环(低级)烷基;任选被低级烷氧基取代的芳基(低级)烷基;含氮的不饱和杂环基团,任选被低级烷基取代;或任选被羟基、低级烷基、卤素或低级烷氧基取代的芳基,其中低级烷氧基取代基可被环氧、羟基、氨基和/或低级烷基氨基取代,前提是当R3和R4各自为氢时,Y为=N--R6,当R1和R2各自为氢或低级烷基且R3为苯基时,Y为=S或=N--R6,以及其药学上可接受的盐,以及其制备方法和包含它们的药物组合物。这些衍生物及其盐可作为强心剂、抗高血压药、脑血管扩张剂和抗血小板药使用。